UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug

All NewsMay 25, 2025

Analyst Selvaraju downgrades UroGen after FDA panel setback dims approval prospects for key bladder cancer drug UGN-102.

Latest Ratings for URGN

DateFirmActionFromTo Jan 2022HC Wainwright & Co.MaintainsBuy Apr 2021HC Wainwright & Co.MaintainsBuy Apr 2020OppenheimerMaintainsOutperform

View More Analyst Ratings for URGN

View the Latest Analyst Ratings

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent